Neurosurgery

AI Brain Health Leader Omniscient Closes Series C Funding Round

Retrieved on: 
вторник, июня 11, 2024
Patient, Map, Omniscience, Magnetic resonance, MRI, Mental health, Growth, Brain, Language, Consciousness, Stroke, FDA, Hospital, Data science, Neurosurgery, SXSW, Neurology, Medical imaging

Omniscient’s revolutionary platform, Quicktome®, leverages AI to convert a standard MRI scan into a detailed map of an individual’s brain networks.

Key Points: 
  • Omniscient’s revolutionary platform, Quicktome®, leverages AI to convert a standard MRI scan into a detailed map of an individual’s brain networks.
  • The latest funding round will support continued growth in the US market and product development for expanded indications.
  • SYDNEY, June 11, 2024 (GLOBE NEWSWIRE) -- Omniscient (“o8t®”), pioneering the use of AI to decode the human brain, today announced the conclusion of a successful Series C funding round, bringing total capital raised to US$60 million.
  • “At Omniscient, we create meaningful AI-driven technologies that are transforming how we understand and care for the brain.

GK Financing LLC, a Subsidiary of American Shared Hospital Services, Announces Extension of Agreement with PeaceHealth Sacred Heart Medical Center at RiverBend

Retrieved on: 
пятница, июня 7, 2024
Patient, Radiosurgery, SAN, AMS, MD, Neurosurgery, Partnership, Quality of life, Cancer, Medical imaging

SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- GK Financing LLC (GKF), a subsidiary of American Shared Hospital Services (NYSE American: AMS), a leading provider of turnkey technology solutions for advanced radiosurgery and radiation oncology services, announced today that it has extended its current agreement with PeaceHealth Sacred Heart Medical Center at RiverBend in Springfield, Ore.

Key Points: 
  • SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- GK Financing LLC (GKF), a subsidiary of American Shared Hospital Services (NYSE American: AMS), a leading provider of turnkey technology solutions for advanced radiosurgery and radiation oncology services, announced today that it has extended its current agreement with PeaceHealth Sacred Heart Medical Center at RiverBend in Springfield, Ore.
  • The new agreement will see the center upgrade its existing Gamma Knife® Perfexion™ system with Esprit, Elekta’s newest Gamma Knife® radiosurgery system.
  • Ray Stachowiak, executive chairman and CEO of American Shared Hospital Services, said: “Our longstanding partnership of 10 years with PeaceHealth Sacred Heart Medical Center at RiverBend will continue to grow with the upgrade of its current Gamma Knife® to the new Esprit system.
  • We are excited to continue our partnership with GKF and appreciate its support in bringing Esprit to our hospital.”

$318.8 Mn Dural Adhesive Agent for Surgical Market - Global and Regional Analysis and Forecasts, 2024-2034 Featuring Prominent Players - Integra LifeSciences, Covidien, Baxter, Johnson & Johnson - ResearchAndMarkets.com

Retrieved on: 
четверг, июня 6, 2024
Surgery, Health, Medical Supplies, Brain damage, Prevalence, Epilepsy, Region, Growth, Ageing, Benchmarking, Tissue engineering, MIS, DSM-IV codes, Brain, DTA, Neurosurgery, Gel, Tetraplegia, Science Translational Medicine, Adhesive

Key Questions Answered in this Report:

Key Points: 
  • Key Questions Answered in this Report:
    What are the main factors driving the demand for dural adhesive agent for surgical market?
  • Who are the key players in the dural adhesive agent for surgical market, and what are their respective market shares?
  • What is the current estimation of the dural adhesive agent for surgical market, and what growth trajectory is projected from 2024 to 2034?
  • Which regions demonstrate the highest adoption rates for dural adhesive agent for surgical market, and what factors contribute to their leadership?

Osteotec announces strategic collaboration with Additive Surgical, bringing cutting-edge 3D-printed spine technology to the UK

Retrieved on: 
четверг, июня 13, 2024
Spine, Neurosurgery, Patient, Titanium, 3D, Porosity, Partnership, Surgeon, Growth, Research, Medical device

This collaboration marks a significant milestone in Osteotec's expansion into the spine sector, promising to deliver unparalleled support and advanced solutions to UK orthopaedic and neurosurgeons.

Key Points: 
  • This collaboration marks a significant milestone in Osteotec's expansion into the spine sector, promising to deliver unparalleled support and advanced solutions to UK orthopaedic and neurosurgeons.
  • Established in 2020, Additive Surgical is the first company in Australia to offer off-the-shelf 3D-printed titanium spinal implants.
  • "This partnership is a testament to our dedication to bringing cutting-edge technologies to the UK market," said Osteotec National Spine Sales Manager Lisa Watts.
  • The partnership with Additive Surgical will see Osteotec exclusively distribute their novel spinal implant technologies across the UK.

Osteotec announces strategic collaboration with Additive Surgical, bringing cutting-edge 3D-printed spine technology to the UK

Retrieved on: 
четверг, июня 13, 2024
Spine, Neurosurgery, Patient, Titanium, 3D, Porosity, Partnership, Surgeon, Growth, Research, Medical device

This collaboration marks a significant milestone in Osteotec's expansion into the spine sector, promising to deliver unparalleled support and advanced solutions to UK orthopaedic and neurosurgeons.

Key Points: 
  • This collaboration marks a significant milestone in Osteotec's expansion into the spine sector, promising to deliver unparalleled support and advanced solutions to UK orthopaedic and neurosurgeons.
  • Established in 2020, Additive Surgical is the first company in Australia to offer off-the-shelf 3D-printed titanium spinal implants.
  • "This partnership is a testament to our dedication to bringing cutting-edge technologies to the UK market," said Osteotec National Spine Sales Manager Lisa Watts.
  • The partnership with Additive Surgical will see Osteotec exclusively distribute their novel spinal implant technologies across the UK.

ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System

Retrieved on: 
суббота, июня 1, 2024
Neurology, Spine, Patient, DBS, Essential tremor, Neurosurgery, Society, Hospital, Laser, SmartFrame, Clinical trial, Assistant, University of Oklahoma, Brain, Walking, Paper, Medical device

“It has completely changed my DBS practice for the better since its release.”

Key Points: 
  • “It has completely changed my DBS practice for the better since its release.”
    “This is a truly exciting milestone for ClearPoint, and one that has been years in the making,” commented Joe Burnett, President and CEO at ClearPoint Neuro.
  • “We set out to prove that we are one of the most innovative and focused companies in the Neurosurgery space.
  • We are now walking into the premier stereotactic neurosurgical conference able to demonstrate new laser therapy, new operating room navigation, new brain modeling software, new access products and new drug delivery preclinical and clinical trial services.
  • This is meaningful innovation that will ultimately benefit our surgical customers and most importantly, many new patients around the world.”
    At ASSFN, the SmartFrame OR and ClearPoint Prism Neuro Laser Therapy System will be showcased at:

Precision Neuroscience Announces World Record for Number of Electrodes Placed On Human Brain

Retrieved on: 
вторник, мая 28, 2024
Patient, Doctor of Philosophy, Electrode, Trial of the century, Sale, MD, Research, Neurosurgery, Brain, Microelectrode, Precision, Mount Sinai Health System, Medical device

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface company Precision Neuroscience Corporation (Precision) and a neurosurgery team from the Mount Sinai Health System now hold the world record for number of electrodes placed on and recording cortical data from a human brain.

Key Points: 
  • NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface company Precision Neuroscience Corporation (Precision) and a neurosurgery team from the Mount Sinai Health System now hold the world record for number of electrodes placed on and recording cortical data from a human brain.
  • The previous published record for number of electrodes recording from a human brain was 2,048, demonstrated by Tan et al in 2023 .
  • The device’s modular design allows for multiple arrays to be placed alongside one another, mapping larger regions of brain activity in high resolution.
  • All Precision Neuroscience research conducted at Mount Sinai is conducted by independent investigators without financial ties to the company.

Chiesi Global Rare Diseases Makes Debut in the Endocrinology Landscape with Multiple Presentations at the Endocrine Society’s ENDO 2024 Meeting

Retrieved on: 
среда, мая 22, 2024
ENDO, Abstract, MACRO, Barrow Neurological Institute, University, Capsule, Safety, FRCP, Neurosurgery, Endocrine system, University of Arizona, FACE, Post hoc analysis, Lipodystrophy, Pharmaceutical industry

BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that three abstracts have been accepted for presentation at the Endocrine Society’s ENDO 2024 Meeting to be held June 1-4, 2024, in Boston, Massachusetts.

Key Points: 
  • BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that three abstracts have been accepted for presentation at the Endocrine Society’s ENDO 2024 Meeting to be held June 1-4, 2024, in Boston, Massachusetts.
  • Attendees can visit Chiesi Global Rare Diseases product booth #526 and the medical booth #428.
  • Poster presentations include the latest data from the Chiesi Management of Acromegaly (MACRO) registry and a presentation on the Lipodystrophy Severity Scoring tool to assess the disease burden in lipodystrophy.
  • To register for ENDO 2024 and view the full meeting schedule, visit the Endocrine Society’s website here .

Nature Medicine Highlights Significant Improvement in Hand and Arm Function After Spinal Cord Injury with Use of ONWARD® ARC-EX® Therapy

Retrieved on: 
понедельник, мая 20, 2024
Doctor of Philosophy, SCI, Sleep, Sensation, Food, University, Safety, MD, Swiss, De novo, Computer engineering, Spinal cord, Movement, EPFL, Euronext, ARC, Electricity, Physical medicine and rehabilitation, Arm, BCI, Neurotechnology, Webcast, Quality of life, Lausanne University Hospital, Neurosurgery, Pharmaceutical industry

EINDHOVEN, the Netherlands, May 20, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces the publication of global Up-LIFT pivotal trial results in Nature Medicine. The study achieved all primary safety and effectiveness endpoints, and ARC-EX Therapy demonstrated significant improvements in upper limb strength, function, and sensation among people with chronic tetraplegia due to cervical SCI.

Key Points: 
  • The study achieved all primary safety and effectiveness endpoints, and ARC-EX Therapy demonstrated significant improvements in upper limb strength, function, and sensation among people with chronic tetraplegia due to cervical SCI.
  • Notably, the number of responders increased to 90% when the definition included participants with improvements in at least one strength or functional outcome*.
  • 87% of participants reported that ARC-EX Therapy delivered improvements in overall quality of life*.
  • “Improvement in arm and hand function is among the highest priorities for people with tetraplegia3 who have endured far too long without effective therapies for functional recovery,” said Dave Marver, CEO, ONWARD Medical.

NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Retrieved on: 
вторник, мая 14, 2024
Partnership, Patient, Research and development, EDEN, Spinal cord stimulator, FDA, Stereoelectroencephalography, NMTC, Neurology, Spinal cord, DSM-IV codes, Brain, Research, Administration, Neurosurgery, Pharmaceutical industry

Total operating expenses in the second quarter of fiscal 2024 were $3.3 million, compared with $3.5 million in the same period of the prior fiscal year.

Key Points: 
  • Total operating expenses in the second quarter of fiscal 2024 were $3.3 million, compared with $3.5 million in the same period of the prior fiscal year.
  • Research and Development (R&D) expense in the second quarter of fiscal 2024 was $1.3 million compared with $1.7 million in the second quarter of fiscal 2023.
  • Selling, General and Administrative (SG&A) expense in the second quarter of fiscal 2024 was $2.0 million compared with $1.8 million in the prior year period.
  • Net loss was $2.9 million for the second quarter of fiscal 2024, compared to a net loss of $3.5 million in the second quarter of fiscal 2023.